Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 439


A favorable cardiometabolic profile is associated with the G allele of the genetic variant rs5068 in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA).

Cannone V, Scott CG, Decker PA, Larson NB, Palmas W, Taylor KD, Wang TJ, Gupta DK, Bielinski SJ, Burnett JC Jr.

PLoS One. 2017 Dec 18;12(12):e0189858. doi: 10.1371/journal.pone.0189858. eCollection 2017.


A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure.

Kawakami R, Lee CYW, Scott C, Bailey KR, Schirger JA, Chen HH, Benike SL, Cannone V, Martin FL, Sangaralingham SJ, Ichiki T, Burnett JC Jr..

Clin Pharmacol Ther. 2017 Dec 11. doi: 10.1002/cpt.974. [Epub ahead of print]


CRRL269: A Novel Designer and Renal Enhancing pGC-A Peptide Activator.

Chen Y, Harty GJ, Huntley BK, Iyer SR, Heublein DM, Harders GE, Meems LMG, Pan S, Sangaralingham SJ, Ichiki T, Burnett JC Jr..

Am J Physiol Regul Integr Comp Physiol. 2017 Nov 29:ajpregu002862017. doi: 10.1152/ajpregu.00286.2017. [Epub ahead of print]


BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?

Sugihara S, Burnett JC Jr.

Eur Heart J. 2017 Aug 7;38(30):2374-2376. doi: 10.1093/eurheartj/ehx276. No abstract available.


Atrial Natriuretic Peptide - Old But New Therapeutic in Cardiovascular Diseases.

Ichiki T, Burnett JC Jr.

Circ J. 2017 Jun 23;81(7):913-919. doi: 10.1253/circj.CJ-17-0499. Epub 2017 May 27.


Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling.

Ichiki T, Huntley BK, Harty GJ, Sangaralingham SJ, Burnett JC Jr.

Physiol Rep. 2017 May;5(9). pii: e13283. doi: 10.14814/phy2.13283. Epub 2017 May 15.


Innovative Therapeutics: Designer Natriuretic Peptides.

Meems LMG, Burnett JC Jr.

JACC Basic Transl Sci. 2016 Dec;1(7):557-567. doi: 10.1016/j.jacbts.2016.10.001.


Divergent effects of a designer natriuretic peptide CD-NP in the regulation of adipose tissue and metabolism.

Glöde A, Naumann J, Gnad T, Cannone V, Kilic A, Burnett JC Jr, Pfeifer A.

Mol Metab. 2017 Jan 4;6(3):276-287. doi: 10.1016/j.molmet.2016.12.010. eCollection 2017 Mar.


Neurohumoral Modulation During Waon Therapy in Chronic Heart Failure - Subanalysis of Waon-CHF Study.

Ichiki T, Burnett JC Jr, Scott CG, Heublein DM, Miyata M, Kinugawa K, Inoue T, Tei C; WAON-CHF Study Investigators.

Circ J. 2017 Apr 25;81(5):709-716. doi: 10.1253/circj.CJ-16-1117. Epub 2017 Feb 16.


Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease.

Chen Y, Burnett JC Jr.

Clin Chem. 2017 Jan;63(1):108-115. doi: 10.1373/clinchem.2016.262907. Epub 2016 Nov 15. Review.


NT-proBNP: The Gold Standard Biomarker in Heart Failure.

McKie PM, Burnett JC Jr.

J Am Coll Cardiol. 2016 Dec 6;68(22):2437-2439. doi: 10.1016/j.jacc.2016.10.001. No abstract available.


Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.

Lee CY, Huntley BK, McCormick DJ, Ichiki T, Sangaralingham SJ, Lisy O, Burnett JC Jr.

Eur Heart J Cardiovasc Pharmacother. 2016 Apr;2(2):98-105. doi: 10.1093/ehjcvp/pvv040. Epub 2015 Dec 10.


Insulin/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway.

Bordicchia M, Ceresiani M, Pavani M, Minardi D, Polito M, Wabitsch M, Cannone V, Burnett JC Jr, Dessì-Fulgheri P, Sarzani R.

Am J Physiol Regul Integr Comp Physiol. 2016 Jul 1;311(1):R104-14. doi: 10.1152/ajpregu.00499.2015. Epub 2016 Apr 13.


Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation.

Grupper A, Zhao YM, Sajgalik P, Joyce LD, Park SJ, Pereira NL, Stulak JM, Burnett JC Jr, Edwards BS, Daly RC, Kushwaha SS, Schirger JA.

Am J Cardiol. 2016 Jun 1;117(11):1765-70. doi: 10.1016/j.amjcard.2016.03.011. Epub 2016 Mar 18.


Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Pre-Clinical Diastolic Dysfunction (Stage B Heart Failure).

Wan SH, McKie PM, Schirger JA, Slusser JP, Hodge DO, Redfield MM, Burnett JC Jr, Chen HH.

JACC Heart Fail. 2016 Jul;4(7):539-547. doi: 10.1016/j.jchf.2015.12.014. Epub 2016 Feb 10.


Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure.

McKie PM, Schirger JA, Benike SL, Harstad LK, Slusser JP, Hodge DO, Redfield MM, Burnett JC Jr, Chen HH.

Eur J Heart Fail. 2016 Apr;18(4):433-41. doi: 10.1002/ejhf.468. Epub 2016 Jan 24.


Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen.

Sangaralingham SJ, Wang BH, Huang L, Kumfu S, Ichiki T, Krum H, Burnett JC Jr.

Peptides. 2016 Feb;76:108-14. doi: 10.1016/j.peptides.2016.01.004. Epub 2016 Jan 13.


Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure.

Andersen IA, Huntley BK, Sandberg SS, Heublein DM, Burnett JC Jr.

Nephrol Dial Transplant. 2016 May;31(5):767-72. doi: 10.1093/ndt/gfv398. Epub 2015 Dec 13.


New Pharmacological Strategies to Increase cGMP.

Buglioni A, Burnett JC Jr.

Annu Rev Med. 2016;67:229-43. doi: 10.1146/annurev-med-052914-091923. Epub 2015 Oct 14. Review.


Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides.

Ichiki T, Huntley BK, Sangaralingham SJ, Burnett JC Jr.

JACC Heart Fail. 2015 Sep;3(9):715-23. doi: 10.1016/j.jchf.2015.03.015.

Supplemental Content

Loading ...
Support Center